Cardiol Therapeut…
USUSDCardiol Therapeutics Inc Class A (US:CRDL) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- cardiolrx.com
- Relaciones con los Inversores
- cardiolrx.com/investors/events-presentations/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Central
- OAKVILLE, Canada
- Consejero Delegado
- David G. Elsley
- Empleados
- 18
- Acciones en Circulación
- 121.51 M a 2025-12-31
- Capital Flotante
- 91.98 M
- Capitalización Bursátil
- 149.46 M USD
- Insiders
- 2.27%
- Inversores Institucionales
- 26.4%
- Industria (SIC)
- Biological Products, (No Diagnostic Substances)
- FCF
- −23.9 M CAD
- Deuda
- 0
- Resultados y FCF — para los 12 meses hasta 31.12.2025 (el último informe de la empresa).
Descripción
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| MMCAP International, Inc… | 13.12% | 15.6 M | 2026-06-30 |
| Tejara Capital Ltd | 4.3% | 5.11 M | 2026-06-30 |
| Ikarian Capital, LLC | 2.8% | 3.33 M | 2026-06-30 |
| Elsley (David) (Director… | ≈1.13% | 1.34 M | 2025-10-17 |
| Boothbay Fund Management… | 0.82% | 975 721 | 2026-06-30 |
| Citadel Advisors Llc | 0.67% | 796 529 | 2026-06-30 |
| Renaissance Technologies… | 0.65% | 772 837 | 2026-06-30 |
| Two Sigma Investments, L… | 0.63% | 746 937 | 2026-06-30 |
| Hamer (Andrew Warwick M.… | ≈0.62% | 739 947 | 2026-08-28 |
| Integrity Alliance, Llc. | 0.33% | 388 492 | 2026-06-30 |
| Morgan Stanley | 0.3% | 355 030 | 2026-06-30 |
| Torreamione (Guilermo) (… | ≈0.28% | 334 309 | 2026-09-08 |
| Goldman Sachs Group Inc | 0.28% | 333 900 | 2026-06-30 |
| Chao (Jennifer M) (Direc… | ≈0.12% | 146 667 | 2026-08-21 |
| Loxam (Teri) (Director o… | ≈0.12% | 146 667 | 2026-08-21 |
| Fidelity Concord Street… | 0.05% | 60 663 | 2026-07-31 |
